RxDoctor Payments Data

Minsoo Kang, MD

Neurology · Niagara Falls, NYNPI 1780681569

Payments from drug & device makers

$130,263in general payments, 2019–2025

Across 528 payments — averaging $246.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$38K
  • Amgen$32K
  • Teva Pharmaceuticals USA, Inc.$25K
  • Lilly USA, LLC$17K
  • Biohaven Pharmaceuticals, Inc.$6K
  • Pfizer$6K
  • plus $7K from 33 others

What the payments were for

  • Consulting fees$8,6227%
  • Speaking & faculty fees$108,77884%
  • Grants$850%
  • Travel & lodging$3,1932%
  • Food & beverage$9,2097%
  • Education$3750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,263 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$14,715
Medicare patients
86
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate15$26,412
BriviactBrivaracetam14$19,423
Ajovy AutoinjectorFremanezumab-Vfrm12$8,407
Aimovig AutoinjectorErenumab-Aooe11$8,157
Levetiracetam51$1,711
Lacosamide35$1,676
Carbidopa-LevodopaCarbidopa/Levodopa48$1,609
Pregabalin44$1,347
Gabapentin47$652
Topiramate33$485
Lamotrigine26$399
Primidone27$396
Duloxetine Hcl20$313
Naratriptan Hcl11$313
RizatriptanRizatriptan Benzoate30$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$5,563$26,41215 claims
UCB, Inc.Briviact$53$19,42314 claims
Upsher-smith Laboratories LLCTopiramate$95$48533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Niagara Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →